Filtered By:
Drug: Bumetanide

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 40 results found since Jan 2013.

Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological Recovery After Stroke Basic Sciences
Conclusions— These data identify a novel role for the WNK3-SPAK/OSR1-NKCC1 signaling pathway in ischemic neuroglial injury and suggest the WNK3-SPAK/OSR1 kinase pathway as a therapeutic target for neuroprotection after ischemic stroke.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Begum, G., Yuan, H., Kahle, K. T., Li, L., Wang, S., Shi, Y., Shmukler, B. E., Yang, S.-S., Lin, S.-H., Alper, S. L., Sun, D. Tags: Acute Cerebral Infarction Basic Sciences Source Type: research

Bumetanide: A review of its neuroplasticity and behavioral effects after stroke.
Authors: Tao D, Liu F, Sun X, Qu H, Zhao S, Zhou Z, Xiao T, Zhao C, Zhao M Abstract Stroke often leads to neuronal injury and neurological functional deficits. Whilst spontaneous neurogenesis and axon regeneration are induced by ischemic stroke, effective pharmacological treatments are also essential for the improvement of neuroplasticity and functional recovery after stroke. However, no pharmacological therapy has been demonstrated to be able to effectively improve the functional recovery after stroke. Bumetanide is a specific Na +-K +-Cl- co-transporter inhibitor which can maintain chloride homeostasis in neuro...
Source: Restorative Neurology and Neuroscience - July 16, 2019 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Chloride Co-transporter NKCC1 Inhibitor Bumetanide Enhances Neurogenesis and Behavioral Recovery in Rats After Experimental Stroke
In conclusion, our results demonstrated that chronic bumetanide treatment enhances neurogenesis and behavioral recovery after experimentally induced stroke in rats.
Source: Molecular Neurobiology - March 10, 2016 Category: Neurology Source Type: research

Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review
CONCLUSIONS: Our review shows that the use of ASMs that act throughout a gabaergic mechanism are inadequate in controlling seizures secondary to neonatal stroke in full-term newborns. Very effective seems to be lidocaine and levetiracetam with an apparent safer profile in short and long term. Bumetanide shows promising results, but they need to be confirmed by phase 3 studies.PMID:36533757 | DOI:10.23750/abm.v93i6.13440
Source: Acta Bio-Medica : Atenei Parmensis - December 19, 2022 Category: General Medicine Authors: Vincenzo Sortino Andrea Pratic ò Silvia Marino Roberta Criscione Martino Ruggieri Francesco Pisani Raffaele Falsaperla Source Type: research